Page last updated: 2024-08-23

epirubicin and Androgen-Independent Prostatic Cancer

epirubicin has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barbanti, G; Bianco, V; Brozzetti, S; De Rubertis, G; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G	1

Trials

1 trial(s) available for epirubicin and Androgen-Independent Prostatic Cancer

Article	Year
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:3 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome	2015

Article

Year

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.

Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:3

Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome

2015